Study Basics
Esketamine
Stats & Results
PPD
Critical Appraisal
100
What type of study is this?

Randomized Clinical Trial

100

What receptor system is primarily targeted by ketamine/esketamine?

NMDA/glutamate system

100

At postpartum day 7, was the rate of PPD higher in the esketamine or placebo group?

Placebo group

100

How do you differentiate baby blues from PPD?

Baby Blues

  • Onset: Starts 2 to 3 days after delivery.
  • Duration: Lasts up to 2 weeks (resolves spontaneously).
  • Symptoms: Mild mood swings, crying spells, irritability, anxiety, and fatigue.


Postpartum Depression (PPD)
  • Onset: Starts anywhere from a few weeks up to 1 year after birth (commonly around 6 weeks).
  • Duration: Lasts longer than 2 weeks and can persist for months or years if left untreated.
  • Symptoms: Severe despair, intense mood swings, severe fatigue, trouble bonding with the baby, withdrawal from loved ones, and thoughts of self-harm.
100

What type of bias does randomization primarily help to reduce?

Selection/confounding bias
200

How many women were randomized?

298 women

200

When was the initial esketamine dose administered in relation to delivery?

Immediately after delivery

200

What percentage of the esketamine group developed PPD at day 7?

23%

200

At what score on the EPDS is it considered suggestive for depression warranting clinical evaluation?

Score of 10 or higher

**10 or lower is low risk for depression

**13 or higher is standard clinical cutoff indicating likely depressive illness

200

What was the placebo control?

Saline

300

What surgical procedure did all participants undergo?

Elective cesarean delivery

300

How long did patients receive postoperative esketamine via PCA?

48 Hours

300

What percentage of the control group developed PPD at day 7?

35.3%

300

What is the maximum possible EPDS score?

30

300

Name one major limitation.

1. Single center study in China.

**This may limit generalizability to other hospitals, populations, healthcare systems, and patient demographics.

2. Confounding factors of PPD were not collected.

**Socioeconomic status, emotional support from spouse/family, stressful events

3. End point for the study was at 42 days (peak of PPD manifestation).

**Long term sustainability of treatment response beyond this period is uncertain

400

Name one characteristic that strengthen this study's internal validity.

1. Randomized

2. Double Blind

3. Placebo controlled

400

What was the total perioperative esketamine regimen used in this study?

0.25 mg/kg IV immediately after delivery,

50 mg of esketamine through a pain pump 2mL/hour for 48 hours.

400

What was the odds ratio for PPD at day 7 and what does this mean?

The odds ratio was 0.55 and this means that the odds of PPD were lower in the esketamine group compared to the control - about 45% lower odds.

400

What were participants' baseline EPDS score? What does this score tell you?

They were very low, around 4 in both groups.

Prior to elective C-section the patients were not suggestive of suffering from depression based on the EPDS. 

**This was a prevention-focused population undergoing elective C-section rather than a treatment trial of women with established depression diagnosis.

400

Why is it important to determine whether a study uses a screening tool vs a formal clinical evaluation?

The EPDS is a screening instrument not a diagnostic tool. An elevated score suggests possible depression but does not confirm MDD. Findings may not directly reflect rates of clinically diagnosed PDD.

500

What was the primary outcome used to assess PPD?

Edinburgh Postnatal Depression Scale (EPDS)

500

Why might the immediate postpartum/perioperative period be an interesting time to give a rapid-acting antidepressant?

It may provide rapid antidepressant effects during a period of increased vulnerability to postpartum depressive symptoms

Ketamine/esketamine also has analgesic effects

500

At which postpartum time point did the significant difference between groups disappear?

After day 7.

There was no significant difference at days 14, 28, or 42.

500
Why does the low baseline EPDS matter when interpreting the results?

It limits how confidently we can generalize the findings to women with moderate/severe depression or established MDD

500

You are the attending psychiatrist. Based ONLY on this study, what is the biggest question you would want answered before routinely recommending perioperative esketamine to prevent PPD?

Whether short-term reduction in depressive symptoms translates into a sustained clinically meaningful reduction in PPD particularly in broader/higher-risk populations.

M
e
n
u